Please login to the form below
Perjeta
This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.
Roche gets EU approval for fixed-dose Herceptin/Perjeta combination
The European Commission has approved a fixed dose combination of Roche’s antibody blockbusters Herceptin and Perjeta under the new brand name Phesgo. ... The new combination treatment, containing Herceptin (trastuzumab) and Perjeta (pertuzumab) with
Latest news
-
EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug
The drug presents a new challenge to Roche’s dominant position in the HER2-positive breast cancer market, which includes a trio of targeted treatments – Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla ... The FDA approval and EMA
-
Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
Final decision due by 18 October. A fixed-dose combination of Roche’s HER2 drugs Herceptin and Perjeta has started a review at the US Food and Drug Administration (FDA), with ... Perjeta has been growing strongly – rising a third to $2.8bn last year
-
Seattle Genetics wins FDA priority review for oral HER2 drug
Herceptin plus Xeloda is a standard treatment regimen for HER2-positive breast cancer, in patients previously treated with Herceptin and Roche’s other HER-2 targeting drugs Perjeta (pertuzumab) and Kadcyla
-
Roche posts minor sales miss in Q4 as biosimilar pressure grows
Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely Perjeta (pertuzumab) for HER2-positive breast cancer, Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy Hemlibra (emicizumab) and
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine). ... This first regulatory approval is based on the DESTINY-Breast01 trial in patients who had previously been treated with Herceptin, Perjeta or Kadcyla.
EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug
Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
Seattle Genetics wins FDA priority review for oral HER2 drug
Roche posts minor sales miss in Q4 as biosimilar pressure grows
More from news
Approximately 22 fully matching, plus 55 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
It has entered into a market dominated by Herceptin and other HER2-targeted therapies such as Perjeta and Tykerb.
-
20 for 2020 – Five pharma companies to watch
treatment pathway in HER2-positive breast cancer as quickly as possible, challenging Roche’s duo of Herceptin and Perjeta (pertuzumab).
-
The Cystic Fibrosis Buyers’ Club
cancer drug Perjeta.
-
Back to the future
In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta
Cortellis Drugs to Watch in 2020 report
20 for 2020 – Five pharma companies to watch
The Cystic Fibrosis Buyers’ Club
Back to the future
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
No results were found
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
